Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: omegatherapeutics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/18/2024 | $12.00 | Outperform | Raymond James |
5/25/2023 | $18.00 → $15.00 | Buy | Jefferies |
12/8/2022 | $11.00 | Buy | H.C. Wainwright |
9/23/2022 | $12.00 | Buy | Chardan Capital Markets |
8/24/2021 | $36.00 | Outperform | Wedbush |
8/24/2021 | $30.00 | Buy | Jefferies |
8/24/2021 | $30.00 | Overweight | Piper Sandler |
8/24/2021 | $22.00 | Neutral | Goldman Sachs |
SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13D/A - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13G - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13G - Omega Therapeutics, Inc. (0001850838) (Subject)
Ratings for Omega Therapeutics (NASDAQ:OMGA) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $9.83, with a high estimate of $12.00 and a low estimate of $7.00. This current average has decreased by 4.1% f
Raymond James analyst Ryan Deschner initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Outperform rating and announces Price Target of $12.
Gainers CareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. Macrogenics (NASDAQ:MGNX) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago. Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million. Omega Therapeutics (NASDAQ:OMGA) shares moved upwards b
HC Wainwright & Co. analyst Robert Burns reiterates Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $12 price target.
Ratings for Omega Therapeutics (NASDAQ:OMGA) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $8.75, a high estimate of $12.00, and a low estimate of
Chardan Capital analyst Keay Nakae maintains Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $7 price target.
Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. The company reported quarterly sales of $2.360 million which beat the analyst consensus estimate of $1.630 million by 44.79 percent. This is a 357.36 percent increase over sales of $516.000 thousand the same period last year.
HC Wainwright & Co. analyst Robert Burns reiterates Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $12 price target.
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
3 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
Raymond James initiated coverage of Omega Therapeutics with a rating of Outperform and set a new price target of $12.00
Jefferies resumed coverage of Omega Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously
H.C. Wainwright initiated coverage of Omega Therapeutics with a rating of Buy and set a new price target of $11.00
Chardan Capital Markets initiated coverage of Omega Therapeutics with a rating of Buy and set a new price target of $12.00
Wedbush initiated coverage of Omega Therapeutics with a rating of Outperform and set a new price target of $36.00
Jefferies initiated coverage of Omega Therapeutics with a rating of Buy and set a new price target of $30.00
Piper Sandler initiated coverage of Omega Therapeutics with a rating of Overweight and set a new price target of $30.00
Goldman Sachs initiated coverage of Omega Therapeutics with a rating of Neutral and set a new price target of $22.00
8-K - Omega Therapeutics, Inc. (0001850838) (Filer)
10-Q - Omega Therapeutics, Inc. (0001850838) (Filer)
8-K - Omega Therapeutics, Inc. (0001850838) (Filer)
8-K - Omega Therapeutics, Inc. (0001850838) (Filer)
8-K/A - Omega Therapeutics, Inc. (0001850838) (Filer)
8-K - Omega Therapeutics, Inc. (0001850838) (Filer)
10-Q - Omega Therapeutics, Inc. (0001850838) (Filer)
8-K - Omega Therapeutics, Inc. (0001850838) (Filer)
DEFA14A - Omega Therapeutics, Inc. (0001850838) (Filer)
DEF 14A - Omega Therapeutics, Inc. (0001850838) (Filer)
All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC, a historically ‘undruggable' target First-known clinical observation of pre-transcriptional gene modulation using a programmable epigenomic mRNA candidate Clinical proof-of-platform established; potential applicability across a broad range of diseases Company to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmabl
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on Tuesday, September 26, 2023, at 8:00 a.m. ET. The webcast will feature members of Omega's leadership team as well as a moderated discussion with Gerard Evan, Ph.D., Principal Group Leader of the Francis Crick Institute in London and Professor of Cancer Biology, King's College London. The live we
CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the addition of Jennifer Nelson, Ph.D., to the Company's executive leadership team in the role of Senior Vice President of Research. She brings over 20 years of experience working with RNA- and DNA-based therapies and technologies, and extensive expertise as a leader in building novel platforms. "Jennifer has an impressive background as a scientist, platform strategist and biopharma leader, with a successful track record of fostering innovation in the field of RNA b
Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024Reinforced diverse capabilities of the OMEGA platform at scientific meetings, including demonstration of precise and durable upregulation of gene expressionStrengthened leadership team with appointment of Kaan Certel, Ph.D., as Chief Business Officer and election of Richard N. Kender to Board of Directors CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA me
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain, or improve people's health before they get sick. In its fifth year, the initiative is grounded in the premise that health should be accessible for all and pursues interventions that prot
Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companiesInitial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunologyGSK and Flagship to jointly fund up to $150 million upfrontLONDON and CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- GSK plc (NYSE:GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
Partnership will Leverage Complementary Expertise in Applied Biology and Engineering to Create and Enhance Multiple Digital Biology Platform Companies WILMINGTON, Mass. and CAMBRIDGE, Mass., July 25, 2024 /PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI), a global semiconductor leader, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic alliance to accelerate the development of a fully digitized biological world. This partnership will bridge ADI's expertise in engineering for analog and digital semiconductors with Flagship Pioneering's expertise in applied biology to foster the discovery of biological insights, new and enhanced measurements, diagnostics,
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its Board of Directors following its annual meeting of stockholders. Mr. Kender's industry knowledge and proven expertise in corporate finance and business development spanning both large pharmaceutical and emerging biotech companies will be instrumental in supporting the Company's business objectives. "Richard has had a long and impressive career in the industry and brings deep expertise across multiple facets of
First exploration agreement initiated under strategic partnership between Flagship and Pfizer to accelerate the development of innovative medicines Collaboration leverages ProFound's proprietary ProFoundry™ Platform to identify potential novel protein therapeutics from the expanded human proteome ProFound and Pioneering Medicines, Flagship's in-house drug development unit will jointly conduct exploration activities CAMBRIDGE, Mass., June 12, 2024 /PRNewswire/ -- Flagship Pioneering and ProFound™ Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, today announced a collaboration to conduct foundational researc
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences. Jefferies Global Healthcare ConferenceDate: Thursday, June 6, 2024Time: 9:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare ConferenceDate: Monday, June 10, 2024Time: 10:40 a.m. ET Live webcasts of the fireside chats will be available on the Investors section of the Company's website at www.omegatherapeutics.com. Archived replays will be available on the sam
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr. Certel brings to Omega extensive biopharmaceutical industry experience and will be responsible for global business development activities including strategic partnerships. "Kaan is an accomplished biopharma executive with deep expertise in business development and corporate strategy, and I am delighted to welcome him to Omega's executive team," said Mahesh Karande, President and Chie
Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024Reinforced diverse capabilities of the OMEGA platform at scientific meetings, including demonstration of precise and durable upregulation of gene expressionStrengthened leadership team with appointment of Kaan Certel, Ph.D., as Chief Business Officer and election of Richard N. Kender to Board of Directors CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA me
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain, or improve people's health before they get sick. In its fifth year, the initiative is grounded in the premise that health should be accessible for all and pursues interventions that prot
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr. Certel brings to Omega extensive biopharmaceutical industry experience and will be responsible for global business development activities including strategic partnerships. "Kaan is an accomplished biopharma executive with deep expertise in business development and corporate strategy, and I am delighted to welcome him to Omega's executive team," said Mahesh Karande, President and Chie
O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar
Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be
Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
Announced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial; clinical proof-of-platform established with potential applicability across a broad range of diseasesAdvanced OMEGA platform capabilities and presented new preclinical data on multiple epigenomic controller programs at medical meetingsFurther strengthened Board of Directors with appointment of Chris Schade as Chairman and addition of Michelle C. Werner CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financ
CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023. Dr. Lepore joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse t
ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer. Urbahns will lead the Company's platform and drug discovery and development efforts to advance first-in-class therapeutics leveraging the company's ProFoundry™ Platform. Urbahns brings three decades of robust drug discovery and development experience to ProFound, with a successful track record in discovering and advancing first-in-human medicines from the lab to the clinic. He joins ProFound after 13 years at Merck KGaA, where he m